Newsroom
Global health news
The latest updates from leading public health agencies and international organizations, gathered automatically every hour. Each story is a short summary with a link to the original publisher.
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis (opens the original article on FDA)
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
FDA Launches New Program to Advance Neuroscience Medical Product Development (opens the original article on FDA)
FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.
FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment (opens the original article on FDA)
FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.
FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women (opens the original article on FDA)
Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.
FDA Issues Final Guidance on Prescription Drug Apps and Software (opens the original article on FDA)
The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery (opens the original article on FDA)
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on…
Safe and effective health products for Canadians: New authorizations between July and September 2026 (opens the original article on Health Canada)
Canadians expect timely access to safe and effective drugs and medical devices. Health Canada is providing a quarterly update on the steps the department is taking to make its regulatory processes more modern and efficient, while maintaining high standards for…
Drugs and medical devices authorized, July 1 to September 30, 2026 (opens the original article on Health Canada)
From July 1 to September 30, 2026, Health Canada approved 16 new drug submissions (14 pharmaceuticals, 2 biologics) and 540 new medical devices, including 27 Class IV medical devices, which present the greatest potential risk. During this period, Health Canada…
Ukraine: Critical health supplies destroyed in ongoing Russian attacks (opens the original article on UN News)
Ongoing and deadly Russian attacks across Ukraine are causing serious healthcare disruption, with more than $1.5 million-worth of medicines and supplies destroyed in four separate strikes on warehouses used by the UN there since July.
FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development (opens the original article on FDA)
The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.
FDA Seeks Public Input to Support Ibogaine Research (opens the original article on FDA)
The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.
Updated 30 Oct 2026, 18:44 EDT. Headlines and short summaries link to the original publishers.